Polyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials

Reuters

09/12

<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials

Polyrizon Ltd. (Nasdaq: PLRZ) has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture & Contain (C&C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528040-en) on September 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566497500"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566497500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566497500?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566497500","market":"nz","top_or_hot":-1,"title":"Polyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLRZ\">Polyrizon Ltd.</a> Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Polyrizon Ltd. (Nasdaq: PLRZ) has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture &amp; Contain (C&amp;C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528040-en) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLRZ\">Polyrizon Ltd.</a> Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Polyrizon Ltd. (Nasdaq: PLRZ) has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture &amp; Contain (C&amp;C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528040-en) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL5vqlpq:1","article_id":"2566497500","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566497500","pubTimestamp":1757676376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Polyrizon Ltd.  has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture & Contain (C&C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","PLRZ":"Polyrizon Ltd.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Polyrizon Ltd.宣布鼻内PL-14过敏阻断剂临床前结果成功，为临床试验铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":0.9,"NDAQ":0.9},"content_text":"Polyrizon Ltd. Announces Successful Preclinical Results for Intranasal PL-14 Allergy Blocker, Paving Way for Clinical Trials\n    \n\n        Polyrizon Ltd. (Nasdaq: PLRZ) has announced promising preclinical results for its PL-14 Allergy Blocker, as part of its Capture & Contain (C&C) platform. Conducted in collaboration with the University of Parma, the study demonstrated targeted deposition in the nasal vestibule, a critical site for early allergen contact. The PL-14 formulation exhibited over 60% deposition in this region, supporting its potential as a preventive treatment for allergic rhinitis. The study, led by Professor Fabio Sonvico, utilized a validated silicone-based human nasal cast to assess the spray deposition profile. Polyrizon plans to continue preclinical efforts and move towards clinical trials. The global allergen blocker market is projected to grow, with an expected value increase from USD 0.14 billion in 2024 to USD 0.21 billion by 2033.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528040-en) on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}